AI agent disclosures in SEC filings
As of 2026-08-13, Silo Pharma, Inc. (SILO) disclosed AI-agent language in 3 SEC filings since 2026-05-14 (source: Agentic 10-K, from SEC EDGAR).
Healthcare & clinical, Operations & supply chain
3 filings since 2025-01-01. All EDGAR filings (opens in a new tab)
Stage and function are keyword-rule labels, not the company’s words.
Sentences copied from the filings, whitespace normalised.
“Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.”
“On April 15, 2026, the Company formed Qwikagentsai Inc.”
“Qwikagentsai is an AI-agent platform focused on enterprise workflow automation through autonomous AI agents.”
Silo Pharma formed wholly-owned subsidiary Qwikagentsai to develop and commercialize web-based AI agent platforms.
“On April 15, 2026, the Company formed Qwikagentsai Inc. (“Qwikagentsai”), a Nevada corporation, as a wholly-owned subsidiary. Qwikagentsai was formed to diversify the Company’s business into artificial intelligence (“AI”) technology including the development and commercialization of web-based AI agent platforms.”
Silo Pharma formed Qwikagentsai, an AI-agent platform for enterprise workflow automation through autonomous AI agents.
“The Company is a developmental-stage biopharmaceutical company with a cryptocurrency treasury strategy. The Company’s therapeutic focus is on developing novel therapeutics that address underserved conditions including post-traumatic stress disorder (“PTSD”), stress-induced anxiety disorders, fibromyalgia, and central nervous system (“CNS”) diseases. The Company is focused on developing (i) an intranasal drug targeting PTSD and stress-induced anxiety disorders (SPC-15); (ii) a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief (SP-26); (iii) an intranasal compound for the treatment of Alzheimer’s disease (SPC-14); and (iv) a CNS-homing peptide targeting the central nervous system in multiple sclerosis (SPU-16). Qwikagentsai is an AI-agent platform focused on enterprise workflow automation through autonomous AI agents. The platform combines persistent memory, intelligent model routing across eight large language model providers, encrypted backups, and browser automation to support scalable AI-driven operations.”
Silo Pharma incurs costs developing AI agent platforms through its subsidiary Qwikagentsai.
“Costs associated with the development of software, technologies and products related to our newly formed wholly-owned subsidiary Qwikagentsai, which was formed to diversify the Company’s business into AI technology including the development and commercialization of web-based AI agent platforms.”
Silo Pharma CEO expresses confidence in advancing its AI agents platform QwikAgents.
““We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.”
Silo Pharma formed wholly-owned subsidiary Qwikagentsai to develop web-based AI agent platforms.
“On April 15, 2026, the Company formed Qwikagentsai Inc. (“Qwikagentsai”), a Nevada corporation, as a wholly-owned subsidiary. Qwikagentsai was formed to diversify the Company’s business into artificial intelligence (“AI”) technology including the development and commercialization of web-based AI agent platforms.”
Silo Pharma formed wholly-owned subsidiary Qwikagentsai to develop web-based AI agent platforms.
“On April 15, 2026, the Company formed its wholly-owned subsidiary, Qwikagentsai to diversify the Company’s business into AI technology including the development and commercialization of web-based AI agent platforms.”
Silo Pharma formed wholly-owned subsidiary Qwikagentsai to develop web-based AI agent platforms.
“On April 15, 2026, we formed Qwikagentsai Inc. (“Qwikagentsai”), a Nevada corporation, as a wholly-owned subsidiary. We acquired 1,000,000 shares of Qwikagentsai’s common stock, par value $0.0001 per share, for aggregate consideration of $100. Qwikagentsai was formed to diversify the Company’s business into AI technology including the development and commercialization of web-based AI agent platforms.”